documents
Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API
40 rows where docket_id = "FDA-2006-N-0304" sorted by posted_date descending
This data as json, CSV (advanced)
Suggested facets: subtype, posted_date, posted_month, comment_start_date, withdrawn, posted_date (date), comment_start_date (date), comment_end_date (date), last_modified (date)
document_type 5
- Supporting & Related Material 26
- Other 8
- Notice 4
- Proposed Rule 1
- Rule 1
agency_id 1
- FDA 40
| id | agency_id | docket_id | title | document_type | subtype | posted_date ▲ | posted_year | posted_month | comment_start_date | comment_end_date | last_modified | fr_doc_num | open_for_comment | withdrawn | object_id |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FDA-2006-N-0304-0051 | FDA | Use of Ozone-Depleting Substances; Removal of Essential-Use Designations FDA-2006-N-0304 | Use of Ozone-Depleting Substances: Removal of Essential-Use Designation (Flunisolide, etc.); Correction | Notice | NCR-Notice of Correction | 2010-09-17T04:00:00Z | 2010 | 9 | 2010-09-17T04:00:00Z | 2011-06-11T16:25:59Z | 2010-23195 | 0 | 0 | 0900006480b51d24 | |
| FDA-2006-N-0304-0050 | FDA | Use of Ozone-Depleting Substances; Removal of Essential-Use Designations FDA-2006-N-0304 | OMB Changes, Executive Order 12866 (E.O.) [Use of Ozone-Depleting Substances; Removal of Essential-Use Designations (Flunisolide, etc.)] - Reference | Other | REF-Reference Material (internal attachments) | 2010-04-27T04:00:00Z | 2010 | 4 | 2010-04-27T04:00:00Z | 2013-07-27T23:17:05Z | 0 | 0 | 0900006480ae1652 | ||
| FDA-2006-N-0304-0045 | FDA | Use of Ozone-Depleting Substances; Removal of Essential-Use Designations FDA-2006-N-0304 | Reference 07 - U.S. Environmental Protection Agency. "The Benefits and Costs of the Clean Air Act: 1990-2010" [FDA-2006-N-0304 Notice of Final Rule, 4/14/2010] | Supporting & Related Material | BKG-Background Material | 2010-04-14T04:00:00Z | 2010 | 4 | 2010-04-14T14:50:58Z | 0 | 0 | 0900006480ad651c | |||
| FDA-2006-N-0304-0040 | FDA | Use of Ozone-Depleting Substances; Removal of Essential-Use Designations FDA-2006-N-0304 | List of References - [FDA-2006-N-0304 Notice of Final Rule 4/14/2010] | Supporting & Related Material | BKG-Background Material | 2010-04-14T04:00:00Z | 2010 | 4 | 2010-04-14T14:50:50Z | 0 | 0 | 0900006480ad5ea8 | |||
| FDA-2006-N-0304-0044 | FDA | Use of Ozone-Depleting Substances; Removal of Essential-Use Designations FDA-2006-N-0304 | Reference 06 - United Nations Environmental Programme, Production and Consumption of Ozone-Depleting Substances: 1986-2004, 2005. [FDA-2006-N-0304 Notice of Final Rule, 4/14/2010] | Supporting & Related Material | BKG-Background Material | 2010-04-14T04:00:00Z | 2010 | 4 | 2010-04-14T14:50:56Z | 0 | 0 | 0900006480ad651b | |||
| FDA-2006-N-0304-0043 | FDA | Use of Ozone-Depleting Substances; Removal of Essential-Use Designations FDA-2006-N-0304 | Reference 04 - Envrios March, Study on the Use of HFCs for Metered Dose Inhalers In the European Union: Final report following submission to the ECCP (European Commission Climate Change Policy Group) [FDA-2006-N-0304 Notice of Final Rule, 4/14/2010] | Supporting & Related Material | BKG-Background Material | 2010-04-14T04:00:00Z | 2010 | 4 | 2010-04-14T14:50:55Z | 0 | 0 | 0900006480ad5eac | |||
| FDA-2006-N-0304-0042 | FDA | Use of Ozone-Depleting Substances; Removal of Essential-Use Designations FDA-2006-N-0304 | Reference 03 - US Department of Commerce, Census Bureau; Economics and Statistics Administration, Pharmaceutical Preparation Manufacturing: 2002 [FDA-2006-N-0304 Notice of Final Rule, 4/14/2010] | Supporting & Related Material | BKG-Background Material | 2010-04-14T04:00:00Z | 2010 | 4 | 2010-04-14T14:50:53Z | 0 | 0 | 0900006480ad5eab | |||
| FDA-2006-N-0304-0049 | FDA | Use of Ozone-Depleting Substances; Removal of Essential-Use Designations FDA-2006-N-0304 | Reference 15 - DeNavas-Walt, C. B. D. Proctor, and J. C Smith, U.S. Census Bureau, Current Population Reports, P60-236(RV), Income, Poverty, and Health Insurance Coverage in the United States: 2008, Table 7, p. 21. 2009 [FDA-2006-N-0304 Notice of Final Rule, 4/14/2010] | Supporting & Related Material | BKG-Background Material | 2010-04-14T04:00:00Z | 2010 | 4 | 2010-04-14T14:51:03Z | 0 | 0 | 0900006480ad6348 | |||
| FDA-2006-N-0304-0046 | FDA | Use of Ozone-Depleting Substances; Removal of Essential-Use Designations FDA-2006-N-0304 | Reference 08 - American Lung Association, "Trends in COPD (Chronic Bronchitis and Emphysema): Morbidity and Mortality," [FDA-2006-N-0304 Notice of Final Rule, 4/14/2010] | Supporting & Related Material | BKG-Background Material | 2010-04-14T04:00:00Z | 2010 | 4 | 2010-04-14T14:50:59Z | 0 | 0 | 0900006480ad651d | |||
| FDA-2006-N-0304-0039 | FDA | Use of Ozone-Depleting Substances; Removal of Essential-Use Designations FDA-2006-N-0304 | Use of Ozone-Depleting Substances; Removal of Essential-Use Designation: Flunisolide, etc. | Rule | NFR-Notice of Final Rule | 2010-04-14T04:00:00Z | 2010 | 4 | 2010-04-14T04:00:00Z | 2011-06-11T16:25:59Z | 2010-08467 | 0 | 0 | 0900006480ad7218 | |
| FDA-2006-N-0304-0041 | FDA | Use of Ozone-Depleting Substances; Removal of Essential-Use Designations FDA-2006-N-0304 | Reference 01 - Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma (EPR-3), NIH Publication No. 07-4051 [FDA-2006-N-0304 Notice of Final Rule, 4/14/2010] | Supporting & Related Material | BKG-Background Material | 2010-04-14T04:00:00Z | 2010 | 4 | 2010-04-14T14:50:52Z | 0 | 0 | 0900006480ad5ea9 | |||
| FDA-2006-N-0304-0047 | FDA | Use of Ozone-Depleting Substances; Removal of Essential-Use Designations FDA-2006-N-0304 | Reference 09 - American Lung Association, "Trends in Asthma Morbidity and Mortality," January 2009 [FDA-2006-N-0304 Notice of Final Rule, 4/14/2010] | Supporting & Related Material | BKG-Background Material | 2010-04-14T04:00:00Z | 2010 | 4 | 2010-04-14T14:51:01Z | 0 | 0 | 0900006480ad651e | |||
| FDA-2006-N-0304-0048 | FDA | Use of Ozone-Depleting Substances; Removal of Essential-Use Designations FDA-2006-N-0304 | Reference 11 - Analysis completed by FDA based on information provided by IMS Health, [FDA-2006-N-0304 Notice of Final Rule, 4/14/2010] | Supporting & Related Material | BKG-Background Material | 2010-04-14T04:00:00Z | 2010 | 4 | 2010-04-14T14:51:02Z | 0 | 0 | 0900006480ad6572 | |||
| FDA-2006-N-0304-0038 | FDA | Use of Ozone-Depleting Substances; Removal of Essential-Use Designations FDA-2006-N-0304 | Graceway Pharmaceuticals, LLC - Supplement Comment re FDA-2006-N-0304-0032 | Other | SUP-Supplement | 2010-02-03T05:00:00Z | 2010 | 2 | 2010-02-03T05:00:00Z | 2013-07-27T23:05:37Z | 0 | 0 | 0900006480a8731b | ||
| FDA-2006-N-0304-0031 | FDA | Use of Ozone-Depleting Substances; Removal of Essential-Use Designations FDA-2006-N-0304 | Use of Ozone-Depleting Substances; Removal of Essential-Use Designations; Extension of Comment Period [re FDA-2006-N-0304-0005 and FDA-2006-N-0304-0001] | Notice | NEC-Notice of Extension | 2009-05-29T04:00:00Z | 2009 | 5 | 2009-05-29T04:00:00Z | 2009-06-30T18:48:45Z | 0 | 0 | 09000064809bf51d | ||
| FDA-2006-N-0304-0028 | FDA | Use of Ozone-Depleting Substances; Removal of Essential-Use Designations FDA-2006-N-0304 | Background Information - American Lung Association, Trends in Asthma Morbidity and Mortality, Epidemiology & Statistics Unit, Research and Program Services, July 2006. | Supporting & Related Material | BKG-Background Material | 2008-12-08T05:00:00Z | 2008 | 12 | 2008-12-08T18:26:08Z | 0 | 0 | 09000064804593a8 | |||
| FDA-2006-N-0304-0024 | FDA | Use of Ozone-Depleting Substances; Removal of Essential-Use Designations FDA-2006-N-0304 | Background Information - National Heart, Lung, and Blood Institute, Expert Panel Report: Update on Selected Topics 2002: Guidelines for the Diagnosis and Management of Asthma, NIH publication No. 02-5074, June 2003 [Article continues in FDA-2006-N-0304-0025] | Supporting & Related Material | BKG-Background Material | 2008-12-08T05:00:00Z | 2008 | 12 | 2008-12-08T18:36:51Z | 0 | 0 | 090000648045939c | |||
| FDA-2006-N-0304-0016 | FDA | Use of Ozone-Depleting Substances; Removal of Essential-Use Designations FDA-2006-N-0304 | Background Information - Reference: Analysis completed by FDA based on information provided by IMS Health, IMS National Sales Perspective (TM), 2005, extracted March 2006. These data are available for purchase from IMS Health. Please send all inquiries to: IMS Health, Attn: Brian Palumbo, Account Manager, 660 West Germantown Pike, Plymouth Meeting, PA 19462 | Supporting & Related Material | BKG-Background Material | 2008-12-08T05:00:00Z | 2008 | 12 | 2008-12-08T18:25:54Z | 0 | 0 | 0900006480459369 | |||
| FDA-2006-N-0304-0020 | FDA | Use of Ozone-Depleting Substances; Removal of Essential-Use Designations FDA-2006-N-0304 | Background Information - Reference: "Surveillance for Asthma — United States, 1980–1999 -- Malaria Surveillance — United States, 1999," MMWR Morbidity andMortality Weekly Report, 2002 | Supporting & Related Material | BKG-Background Material | 2008-12-08T05:00:00Z | 2008 | 12 | 2008-12-08T18:25:59Z | 0 | 0 | 0900006480459377 | |||
| FDA-2006-N-0304-0023 | FDA | Use of Ozone-Depleting Substances; Removal of Essential-Use Designations FDA-2006-N-0304 | Background Information - References | Supporting & Related Material | BKG-Background Material | 2008-12-08T05:00:00Z | 2008 | 12 | 2008-12-08T18:26:02Z | 0 | 0 | 0900006480459387 | |||
| FDA-2006-N-0304-0022 | FDA | Use of Ozone-Depleting Substances; Removal of Essential-Use Designations FDA-2006-N-0304 | Background Information - National Heart, Lung, and Blood Institute, Expert Panel Report 2: Guidelines for the Diagnosis and Management of Asthma, NIH publication No. 97-4051, July 1997 - Continued [Article begins in FDA-2006-N-0304-0027] | Supporting & Related Material | BKG-Background Material | 2008-12-08T05:00:00Z | 2008 | 12 | 2008-12-08T18:35:31Z | 0 | 0 | 0900006480459385 | |||
| FDA-2006-N-0304-0027 | FDA | Use of Ozone-Depleting Substances; Removal of Essential-Use Designations FDA-2006-N-0304 | Background Information - National Heart, Lung, and Blood Institute, Expert Panel Report 2: Guidelines for the Diagnosis and Management of Asthma, NIH publication No. 97-4051, July 1997 (continued in FDA-2006-N-0304-0022) | Supporting & Related Material | BKG-Background Material | 2008-12-08T05:00:00Z | 2008 | 12 | 2008-12-08T18:33:28Z | 0 | 0 | 09000064804593a5 | |||
| FDA-2006-N-0304-0026 | FDA | Use of Ozone-Depleting Substances; Removal of Essential-Use Designations FDA-2006-N-0304 | Background Information - United Nations Environmental Programme, Production and Consumption of Ozone-Depleting Substances: 1986-2004, 2005 | Supporting & Related Material | BKG-Background Material | 2008-12-08T05:00:00Z | 2008 | 12 | 2008-12-08T18:26:06Z | 0 | 0 | 09000064804593a3 | |||
| FDA-2006-N-0304-0025 | FDA | Use of Ozone-Depleting Substances; Removal of Essential-Use Designations FDA-2006-N-0304 | Background Information - National Heart, Lung, and Blood Institute, Expert Panel Report: Update on Selected Topics 2002: Guidelines for the Diagnosis and Management of Asthma, NIH publication No. 02-5074, June 2003 - continued | Supporting & Related Material | BKG-Background Material | 2008-12-08T05:00:00Z | 2008 | 12 | 2008-12-08T18:26:05Z | 0 | 0 | 090000648045939f | |||
| FDA-2006-N-0304-0017 | FDA | Use of Ozone-Depleting Substances; Removal of Essential-Use Designations FDA-2006-N-0304 | Background Information - Reference: Rozek, R.P., and E.R. Bishko, Economics Issues Raised in the FDA's Proposed Rule on Removingthe Essential-Use Designation for Albuterol MDIs, National Economic Research Associates, August 13, 2004 (FDA Docket No. 2003P-0029 C 25) | Supporting & Related Material | BKG-Background Material | 2008-12-08T05:00:00Z | 2008 | 12 | 2008-12-08T18:25:55Z | 0 | 0 | 090000648045936a | |||
| FDA-2006-N-0304-0019 | FDA | Use of Ozone-Depleting Substances; Removal of Essential-Use Designations FDA-2006-N-0304 | Background Information - Reference: U.S. Environmental Protection Agency, The Benefits and Costs of the Clean nAir Act: 1990-2010. (http://www.epa.gov/air/sect812/copy99.html) (November 1999). | Supporting & Related Material | BKG-Background Material | 2008-12-08T05:00:00Z | 2008 | 12 | 2008-12-08T18:25:57Z | 0 | 0 | 0900006480459373 | |||
| FDA-2006-N-0304-0021 | FDA | Use of Ozone-Depleting Substances; Removal of Essential-Use Designations FDA-2006-N-0304 | Background Information - Reference: DeNavas-Walt, C., B.D. Proctor, and C.H. Lee, U.S. Census Bureau, Current Population Reports, P60-229, Income, Poverty, and Health Insurance Coverage in the United States: 2004, p. 18, 2005 | Supporting & Related Material | BKG-Background Material | 2008-12-08T05:00:00Z | 2008 | 12 | 2008-12-08T18:26:00Z | 0 | 0 | 0900006480459378 | |||
| FDA-2006-N-0304-0018 | FDA | Use of Ozone-Depleting Substances; Removal of Essential-Use Designations FDA-2006-N-0304 | Background Information - Reference: "Chronic Obstructive Pulmonary Disease Surveillance — United States, 1971–2000" MMWR Morbidity and Mortality Weekly Report, CDC | Supporting & Related Material | BKG-Background Material | 2008-12-08T05:00:00Z | 2008 | 12 | 2008-12-08T18:25:56Z | 0 | 0 | 0900006480459371 | |||
| FDA-2006-N-0304-0014 | FDA | Use of Ozone-Depleting Substances; Removal of Essential-Use Designations FDA-2006-N-0304 | Graceway Pharmaceuticals, LLC (Graceway) - Addendum to Comment | Other | AMD-Amendment | 2008-07-21T04:00:00Z | 2008 | 7 | 2008-07-21T04:00:00Z | 2008-12-09T19:09:49Z | 0 | 0 | 0900006480650364 | ||
| FDA-2006-N-0304-0015 | FDA | Use of Ozone-Depleting Substances; Removal of Essential-Use Designations FDA-2006-N-0304 | Abbott - Withdrawal | Other | WDL-Withdrawal | 2008-07-21T04:00:00Z | 2008 | 7 | 2008-07-21T04:00:00Z | 2013-07-27T22:18:53Z | 0 | 0 | 0900006480680030 | ||
| FDA-2006-N-0304-0012 | FDA | Use of Ozone-Depleting Substances; Removal of Essential-Use Designations FDA-2006-N-0304 | Graceway Pharmaceuticals, LLC - Request for Extension of Comment Due Date | Other | EXT-Request for Extension Comment Due Date | 2008-07-21T04:00:00Z | 2008 | 7 | 2008-07-21T04:00:00Z | 2013-07-27T20:44:31Z | 0 | 0 | 09000064804593ad | ||
| FDA-2006-N-0304-0013 | FDA | Use of Ozone-Depleting Substances; Removal of Essential-Use Designations FDA-2006-N-0304 | Graceway Pharmaceuticals - Request for Extension of Comment Due Date | Other | EXT-Request for Extension Comment Due Date | 2008-07-21T04:00:00Z | 2008 | 7 | 2008-07-21T04:00:00Z | 2013-07-27T20:44:31Z | 0 | 0 | 09000064804593bc | ||
| FDA-2006-N-0304-0009 | FDA | Use of Ozone-Depleting Substances; Removal of Essential-Use Designations FDA-2006-N-0304 | University of Alabama at Birmingahm (UAB) - Letter | Other | LET-Letter | 2008-06-02T04:00:00Z | 2008 | 6 | 2008-06-02T04:00:00Z | 2008-06-03T00:17:05Z | 0 | 0 | 09000064804593b9 | ||
| FDA-2006-N-0304-0010 | FDA | Use of Ozone-Depleting Substances; Removal of Essential-Use Designations FDA-2006-N-0304 | Lisa Delaney Correspondence to the Center for Drug Evaluation and Research - Electronic Letter | Other | ELET-Electronic Letter | 2008-06-02T04:00:00Z | 2008 | 6 | 2008-06-02T04:00:00Z | 2008-06-03T00:17:06Z | 0 | 0 | 090000648045aaf8 | ||
| FDA-2006-N-0304-0002 | FDA | Use of Ozone-Depleting Substances; Removal of Essential-Use Designations FDA-2006-N-0304 | See FDA-2006-N-0304-0030 | Supporting & Related Material | 2007-09-26T00:00:00Z | 2007 | 9 | 2009-03-11T19:34:10Z | 0 | 1 | 090000648045b7c1 | ||||
| FDA-2006-N-0304-0005 | FDA | Use of Ozone-Depleting Substances; Removal of Essential-Use Designations FDA-2006-N-0304 | Use of Ozone-Depleting Substances; Removal of Essential-Use Designations; Extension of Comment Period | Notice | NEC-Notice of Extension | 2007-08-07T04:00:00Z | 2007 | 8 | 2007-08-06T04:00:00Z | 2007-09-11T03:59:59Z | 2009-05-29T18:06:16Z | 0 | 0 | 09000064804597f1 | |
| FDA-2006-N-0304-0004 | FDA | Use of Ozone-Depleting Substances; Removal of Essential-Use Designations FDA-2006-N-0304 | Use of Ozone-Depleting Substances; Removal of Essential-Use Designations; Public Meeting | Notice | NM-Notice of Meeting | 2007-07-09T04:00:00Z | 2007 | 7 | 2007-07-06T04:00:00Z | 2008-06-03T00:07:41Z | 0 | 0 | 09000064804593af | ||
| FDA-2006-N-0304-0001 | FDA | Use of Ozone-Depleting Substances; Removal of Essential-Use Designations FDA-2006-N-0304 | Use of Ozone-Depleting Substances; Removal of Essential-Use Designations | Proposed Rule | NPR-Notice of Proposed Rule-Making | 2007-06-06T04:00:00Z | 2007 | 6 | 2007-06-06T04:00:00Z | 2007-08-11T03:59:59Z | 2008-12-08T18:38:09Z | 0 | 0 | 09000064804592b2 | |
| FDA-2006-N-0304-0006 | FDA | Use of Ozone-Depleting Substances; Removal of Essential-Use Designations FDA-2006-N-0304 | Environmental Assessment [FDA-2006-N-0304-0001] | Supporting & Related Material | EA-Environmental Assessment | 2007-06-06T04:00:00Z | 2007 | 6 | 2008-06-03T00:14:44Z | 0 | 0 | 090000648045935f | |||
| FDA-2006-N-0304-0008 | FDA | Use of Ozone-Depleting Substances; Removal of Essential-Use Designations FDA-2006-N-0304 | Findings of No Significant Impact [FDA-2006-N-0304-0001] | Supporting & Related Material | FONS-Finding of no Significant Impact | 2007-06-06T04:00:00Z | 2007 | 6 | 2008-06-03T00:16:19Z | 0 | 0 | 0900006480459367 |
Advanced export
JSON shape: default, array, newline-delimited, object
CREATE TABLE documents (
id TEXT PRIMARY KEY,
agency_id TEXT,
docket_id TEXT REFERENCES dockets(id),
title TEXT,
document_type TEXT,
subtype TEXT,
posted_date TEXT,
posted_year INTEGER,
posted_month INTEGER,
comment_start_date TEXT,
comment_end_date TEXT,
last_modified TEXT,
fr_doc_num TEXT,
open_for_comment INTEGER,
withdrawn INTEGER,
object_id TEXT
);
CREATE INDEX idx_docs_agency ON documents(agency_id);
CREATE INDEX idx_docs_docket ON documents(docket_id);
CREATE INDEX idx_docs_date ON documents(posted_date);
CREATE INDEX idx_docs_year ON documents(posted_year);
CREATE INDEX idx_docs_type ON documents(document_type);
CREATE INDEX idx_docs_frnum ON documents(fr_doc_num);